|
Press Releases |
|
|
|
Tuesday, December 1, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Monday, November 30, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Wednesday, November 11, 2020 |
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
Monday, November 2, 2020 |
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
The South China Sea: A Nuanced Understanding Required
Apr 24, 2024 21:12 HKT/SGT
|
|
|
Kontent.ai Introduces Mission Control and New Brand Identity, Leading a New Era of Content Management
Apr 24, 2024 20:51 HKT/SGT
|
|
|
业聚医疗合资企业在中国内地启动TricValve临床试验
Apr 24, 2024 19:07 HKT/SGT
|
|
|
業聚醫療合資企業在中國內地啟動TricValve臨床試驗
Apr 24, 2024 19:04 HKT/SGT
|
|
|
Legacy Credit Emerges as a Substantial Shareholder in VCI Global
Apr 24, 2024 19:00: JST
|
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Apr 24, 2024 18:59 HKT/SGT
|
|
|
Legacy Credit Emerges as a Substantial Shareholder in VCI Global
Apr 24, 2024 18:00 HKT/SGT
|
|
|
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
|
|
|
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
|
|
|
三菱重工、タイの超大型複合火力発電所プロジェクトでM701JAC形GTCCの7系列目が運転開始
Apr 24, 2024 14:30: JST
|
|
|
トヨタ・モビリティ基金、「自転車事故削減に向けた新たな官民連携のあり方」に関するシンポジウムを開催
Apr 24, 2024 14:00: JST
|
|
|
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
|
|
|
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
|
|
|
一站式金融媒体发布平台「全球速发布」重磅推出!
Apr 24, 2024 10:52 HKT/SGT
|
|
|
一站式金融媒體發佈平台「全球速發佈」重磅推出!
Apr 24, 2024 10:35 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|